Business
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2
New Taipei City, Taiwan, March 27, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven
About this update from Jyong Biotech Ltd.
[{"type":"text","content":"New Taipei City, Taiwan, March 27, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today provided an update on the plant-derived innovative drug MCS®-2 of its multiple competitive advantages and its potential clinical benefits in the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS). Pioneering Plant-Based TherapeuticsDeveloped in Taiwan, MCS®-2 is the world’s only oral botanical new drug to have completed a global Phase III clinical trial for benign prostatic hyperplasia (BPH). Jyong Biotech has conducted four Phase III clinical trials (API-1) in the U.S. and Taiwan, including two pivotal trials (one in the U.S. and one in Taiwan) and two open-label extension studies (one in the U.S. and one in Taiwan), and completion of the Phase III clinical trial report was achieved in 2017. In the U.S., trials were conducted across 27 centers in 19 states, involving over 200 urologists. In Taiwan, trials took place in 12 major hospitals, including multiple medical centers, with participation from more than 70 urologists (over one-tenth of all urologists in Taiwan). The Company believes that this extensive physician network lays a strong foundation for future commercialization and expansion into new indications. Rigorous Scientific Validation and Clinical Evidence:Jyong Biotech strictly adheres to FDA guidelines and standards throughout its drug development process. MCS®-2 (API-1) has completed Phase I through Phase III clinical validation, along with more than ten international toxicology studies. Across all four Phase III trials in Taiwan and the U.S., the drug demonstrated excellent safety, with no serious adverse events, supporting its suitability for long-term use.Global Patent Protection:The company believes that its core technology significantly enhances bioavailability and enables the development of multiple formulations and indications, including oral formulations, injectable forms, and bladder instillation therapies. These innovations are protected by patents across the Americas, Asia, Europe, and other regions, forming a global portfolio that effectively overcomes existing patent barriers established by major pharmaceutical...